No profile data available.
Lyell Immunopharma, Inc. (LYEL) is a healthcare company in the blood cancer treatment drugs industry, based in South San Francisco, United States, with about 161 full-time employees.
It reported revenue of $36,000 for fiscal year 2025, and net income of -$274.45 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $4,000, down 50.0% from a year before. Its market capitalization was $213.44 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Lyell Immunopharma reported $36,000 in revenue for fiscal year 2025. In Q2 2026 revenue was $4,000.
$213.44 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include OmniAb, Inc. (OABI), Sellas Life Sciences Group, Inc. (SLS), ADC Therapeutics SA (ADCT), Cellectis S.a. (CLLS).